RecruitingPhase 2Drug trialEffect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are OverweightPhase 2, multicenter, randomized, double-blind, placebo-controlled study evaluating once-weekly subcutaneous retatrutide (LY3437943) at multiple maintenance dose levels versus placebo in adults with obesity or overweight with weight-related comorbidities (without type 2 diabetes), alongside standardized diet and physical activity counseling.